(651) 348-6928 BradQ@DuNordRe.com

News & Updates
SUBSCRIBE AND STAY INFORMED

Subscribe to our monthly newsletter to stay up-to-date with the latest industry news and market trends.

Can Weight Loss Drugs Increase Your Reinsurance Costs?

The use of weight loss drugs like Wegovy is expanding rapidly. The March 29th edition of the Wall Street Journal reported that Elevance and Kaiser Permanente are expanding their coverage for people with heart-related conditions for Medicare Advantage and commercial...

The Wave Continues, and the FDA is Gearing Up!

GENE AND CELL THERAPY: The Wave Continues, and the FDA is Gearing Up! Are you concerned about whether you're ready for the coming wave of expensive therapies? The tides have been changing, bringing new challenges and opportunities. The FDA recently received increased...

Can Weight Loss Drugs Increase Your Reinsurance Costs?

The use of weight loss drugs like Wegovy is expanding rapidly. The March 29th edition of the Wall Street Journal reported that Elevance and Kaiser Permanente are expanding their coverage for people with heart-related conditions for Medicare Advantage and commercial plans. While not a blanket approval, it may be the “nose in the tent” that leads to rapidly expanding usage. It appears some large health plans may believe it is better to pay $14k—$16k annually for Wegovy than to have a major heart event. If the major plans cover GLP-1 drugs, will smaller plans be far behind? How could this...

read more

The Wave Continues, and the FDA is Gearing Up!

GENE AND CELL THERAPY: The Wave Continues, and the FDA is Gearing Up! Are you concerned about whether you're ready for the coming wave of expensive therapies? The tides have been changing, bringing new challenges and opportunities. The FDA recently received increased funding, allowing for 60 additional reviewers of proposed Gene and Cell Therapies. There are currently 694 Gene and Cell Therapies (GCT) in the trial phase, of which 48 are late-stage and five in stage III. Could the FDA be gearing up for faster-than-anticipated approvals? The target market for GCT is also expanding beyond...

read more